Successful term vaginal delivery following remission from ultra-high-risk metastatic choriocarcinoma: a rare case of preserved fertility and favourable obstetric outcome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262569Keywords:
Choriocarcinoma, Gestational trophoblastic neoplasia, Metastatic GTN, EP/EMA, Pregnancy after GTN, Vaginal deliveryAbstract
Metastatic choriocarcinoma represents one of the most aggressive forms of gestational trophoblastic neoplasia (GTN), particularly when associated with distant spread such as pulmonary and central nervous system involvement. Advances in multi-agent chemotherapy have significantly improved survival; however, data regarding fertility and pregnancy outcomes following treatment for ultra-high-risk disease remain limited. We reported a young woman diagnosed with metastatic choriocarcinoma following a medical termination of pregnancy, who achieved complete remission after EP/EMA chemotherapy and subsequently conceived spontaneously. Serial β-hCG levels showed a rapid decline from 443,096 IU/l to normal values, confirming treatment response. The interval between completion of chemotherapy and conception was approximately two years. Her antenatal course was clinically stable. She presented in labour at term and progressed to vaginal delivery despite meconium-stained liquor, with reassuring fetal status throughout. Both mother and neonate had an uncomplicated postpartum course. This case highlights the possibility of preserved reproductive function and favourable obstetric outcomes even after treatment for ultra-high-risk metastatic GTN.
References
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.
Ngan HYS, Seckl MJ, Berkowitz RS. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynecol Obstet. 2021;155(1):86-93.
Newlands ES, Bower M, Holden L, Short D, Brock C, Rustin GJ, et al. The management of high-risk gestational trophoblastic tumours (GTT). Int J Gynaecol Obstet. 1998;60(1):65-70.
Xue W, Yang JJ, Zhao J, Ren T, Feng FZ, Wan XR, et al. Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia. Zhonghua Fu Chan Ke Za Zhi. 2018;53(6):377-83.
Malovrh EP, Lukinovič N, Sobočan M, Knez J. Outcomes of gestational trophoblastic disease management: a single-centre review. Medicina (Kaunas). 2023;59(9):1632.
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654-62.
Royal College of Obstetricians and Gynaecologists (RCOG). The management of gestational trophoblastic disease. Green-top Guideline No. 38. London: RCOG; 2020.
Enuset A, Duck L, Petre C, Machiels JP, Goffin F. Multidrug resistant gestational trophoblastic neoplasia: failure of immunotherapy and success of high-dose chemotherapy. Front Oncol. 2024;14:1391408.
Braga A, Mora P, de Melo AC, Nogueira-Rodrigues A, Amim-Junior J, Rezende-Filho J, et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol. 2019;10(2):28-37.
Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021;137(2):355-70.